← Leaderboards
Matthew J. Frank
Stanford University
$844,890
Attributed
$844,890
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $169K · FY2020–24$200K$150K$100K$50K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$844,890 · 1
By mechanism
K08$844,890 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Maximilian Diehn$12,346,945
- Hanlee Ji$24,780,644
- Nancy R Zhang$4,610,814
- Melanie Hayden Gephart$6,763,817
- Marlene Rabinovitch$40,032,014
Others in their field
Other Emerging Leaders on “S Lymphoma”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$22,138,591
- Leonard Freedman · Leidos Biomedical Research, Inc.$10,332,151
- Kathleen Nicol · Research Inst Nationwide Children'S Hosp$7,187,946
- Javeed Iqbal · University Of Nebraska Medical Center$5,566,166
- John Karijolich · Vanderbilt University Medical Center$5,446,739
Research focus
S LymphomaCohortCancer VaccinesAffectAdultClinical TrialsB-Cell Acute Lymphoblastic LeukemiaBioinformaticsAntigen TargetingBloodAppropriate DoseB Lymphoid MalignancyBone Marrow TransplantationAftercareAntigensCareerCar T Cell TherapyCd19 AntigensCd19 GeneCd22 GeneCd58 GeneChimeric Antigen ReceptorChimeric Antigen Receptor T CellsClinical Trials Design
Grant awards (5)
Lymphoma Antigen Density and Circulating Tumor DNA Profiling As Determinants of Novel CAR Therapies$168,978
K08 · FY2024 · CA · contact PI
Lymphoma Antigen Density and Circulating Tumor DNA Profiling As Determinants of Novel CAR Therapies$168,978
K08 · FY2023 · CA · contact PI
Lymphoma Antigen Density and Circulating Tumor DNA Profiling As Determinants of Novel CAR Therapies$168,978
K08 · FY2022 · CA · contact PI
Lymphoma Antigen Density and Circulating Tumor DNA Profiling As Determinants of Novel CAR Therapies$168,978
K08 · FY2021 · CA · contact PI
Lymphoma Antigen Density and Circulating Tumor DNA Profiling As Determinants of Novel CAR Therapies$168,978
K08 · FY2020 · CA · contact PI